hotspot -WSS

hotspot

author：comprehensive 2025-09-14 18:30:48 - browse：5613

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： First transplant of an entire human eye performed

WSS

Medical school prerequisites are outdated

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

OTC birth control: A brief history of over the counter pill design

What Mike Pence has said that could be used in a Donald Trump trial

Biden calls for immediate release of Niger's president amid apparent coup

Wikipedia

hotspot

hotspot

Drug repurposing or repositioning? The language matters

Attacks on the drug industry will lead to fewer breakthroughs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

BioMarin wins approval for gene therapy to treat hemophilia A

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Cancer drug shortages should be causing more outrage

After decades in use, heart stents finally beat placebo

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Experimental asthma app from Apple and Anthem shows promise

focus

A letter from the executive editor: STAT UnitedHealth investigation

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Ohio still needs to do more to protect the right to abortion

Gilgo Beach: Police identify another victim in serial killing investigation

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

CVS, Rite Aid closures threaten to worsen pharmacy deserts

knowledge

Wikipedia

focus

entertainment